
Customize View
Recently disclosed strategic alliances only (within the last two years)
Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
Strategic Alliance Name
Company Name
Primary Industry
Source
23andMe Holding Co. (NasdaqGS:ME)
GSK plc (LSE:GSK)
Health Care Services
GSK plc (LSE:GSK) - Form Doc
Business Description: 23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company’s therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.
Aceragen, Inc.
GlaxoSmithKline Intellectual Property Development Limited
Biotechnology
Aceragen, Inc. 2020 Form 10-K
Business Description: Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich’s Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
AGP Limited (KASE:AGP)
GSK plc (LSE:GSK)
Pharmaceuticals
AGP Limited (KASE:AGP) - Form Doc
Business Description: AGP Limited manufactures, sells, wholesales, distributes, exports, imports, markets, deals in pharmaceutical and healthcare products under licensing arrangements in Pakistan. The company offers products in the areas of aminoglycosides, angiotensin II antagonist, anti epileptics, anti-gout, anti-infective antidiarrheal, anti-inflammatory enzyme, antidiarrheal microorganisms, antifibrinolytic, antihistamines systemic, antileuk anti-ashtm sys, antineoplastic agent, anti-obesity, antirheumatic non-steroid, antispasmodic and anticholinergic plain, atypical antipsychotics, biguanide and S-urea combs, bile stone therapy, calcium, calcium channel blocker, cephalosporins oral and inject, DPP-IV Inh and biguanide comb, DPP-IV Inh A-diab plain, expectorants, eye tonics and eye vitamins, fluoroquinolones, glitazone and biguanide combinations, hepatitis C antivirals, iron combination products, muscle relaxants central, narcotic analgesic, and non-narcotic analgesic. It also provides nucleoside reverse transcriptase inhibitors, Oth anti-anaem folic acid, stomach disorder products, proton pump inhibitor, psycholeptic antidepressant, SGLT2 inhibitors antidiabetic and biguanide, SSRI antidepressants, sulphonylurea, systemic vasoprotectives, tonic, topical antihaemorrhoidal, urinary anti-infectives, urinary incontinence prd, vitamin B12, vitamin D3, and xanthine-systemic, and vitamin C combination products. AGP Limited was founded in 1989 and is headquartered in Karachi, Pakistan.
Alector, Inc. (NasdaqGS:ALEC)
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer’s disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Alibaba Health Information Technology Limited (SEHK:241)
GSK plc (LSE:GSK)
Drug Retail
Alibaba Health Information Technology Limited (SEHK:241) 2020 Form Doc
Business Description: Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. It offers range of prescription drugs, over-the-counter drugs, nutritional supplements, medical devices, contact lenses, and various other health-related products through its online stores on Tmall.com and offline pharmacy outlets to business-to-customer and business-to-business customers; and pharmaceutical products, medical devices and healthcare products, health food, adult and family planning products, contact lenses, and medical and healthcare services through its e-commerce platform. The company also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, registration, vaccination, and traditional Chinese medicine through various channels, such as Taobao, Tmall, Alipay, Dr. Deer APP, AMap, Freshippo, DingTalk, and Quark. In addition, it engages in the digital tracking business; provision of network hospital, healthcare related internet information, internet information, and healthcare related technical services; operation of internet hospitals; and asset management services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.
AnaptysBio, Inc. (NasdaqGS:ANAB)
GSK plc (LSE:GSK)
Biotechnology
AnaptysBio, Inc. (NasdaqGS:ANAB) 2020 Form 10-K
Business Description: AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Aridis Pharmaceuticals, Inc. (OTCPK:ARDS)
Glaxosmithkline Biologicals S.A.
Biotechnology
Aridis Pharmaceuticals, Inc. (OTCPK:ARDS) 2020 Form 10-K
Business Description: Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
Aridis Pharmaceuticals, Inc. (OTCPK:ARDS)
GSK plc (LSE:GSK)
Biotechnology
Aridis Pharmaceuticals, Inc. (OTCPK:ARDS) 2020 Form 10-K
Business Description: Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
Biocon Limited (NSEI:BIOCON)
GSK plc (LSE:GSK)
Biotechnology
Biocon Limited (NSEI:BIOCON) - Form 
Business Description: Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, the company is involved in the integrated discovery, development, and manufacturing services for small and large molecules. It serves customers in approximately 120 countries. The company was incorporated in 1978 and is headquartered in Bengaluru, India.
Biomedical Advanced Research And Development Authority
GSK plc (LSE:GSK)
Diversified Support Services
GSK plc (LSE:GSK) - Form Doc
Business Description: Biomedical Advanced Research And Development Authority is headquartered in the United States.
Clinton Health Access Initiative, Inc.
GSK plc (LSE:GSK)
Diversified Support Services
GSK plc (LSE:GSK) - Form Doc
Business Description: Clinton Health Access Initiative, Inc., a nonprofit corporation, provides access for the care and treatment of HIV/AIDS, malaria, and other illnesses in low- and middle-income countries. It operates programs across various health areas, including infectious diseases, women and children’s health, universal health coverage, and non-communicable diseases. Clinton Health Access Initiative, Inc. also offers price reductions for medicines, diagnostics, vaccines, devices, or other life-saving health products and services. Clinton Health Access Initiative, Inc. was founded in 2002 and is based in Boston, Massachusetts.
CureVac AG
Glaxosmithkline Biologicals S.A.
Biotechnology
CureVac AG 2020 Form F-1
Business Description: CureVac AG, a clinical stage biotechnology company, develops various medicines based on the messenger ribonucleic acid (mRNA) to enhance the lives of people. Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company’s partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company is headquartered in Tübingen, Germany. CureVac AG is a subsidiary of CureVac N.V.
CureVac N.V. (NasdaqGM:CVAC)
Glaxosmithkline Biologicals S.A.
Biotechnology
CureVac N.V. (NasdaqGM:CVAC) 2021 Form F-1
Business Description: CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
CureVac N.V. (NasdaqGM:CVAC)
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Daiichi Sankyo Company, Limited (TSE:4568)
GSK plc (LSE:GSK)
Pharmaceuticals
GSK plc (LSE:GSK) 2016 Form 20-F
Business Description: Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Epizyme, Inc.
Glaxo Group Limited
Biotechnology
Epizyme, Inc. 2021 Form 10-K
Business Description: Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high-risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small-cell lung cancer, and others. In addition, the company develops Tazemetostat for patients with INI1-negative tumors in adults and pediatrics; a PRMT5 inhibitor for patients with solid tumors; and a PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc.
Exagen Inc. (NasdaqGM:XGN)
GlaxoSmithKline LLC
Biotechnology
Key DevelopmentStrategic Alliances Nov-22-2019
Business Description: Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient’s blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Faes Farma, S.A. (BME:FAE)
GSK plc (LSE:GSK)
Pharmaceuticals
Faes Farma, S.A. (BME:FAE) - Form 
Business Description: Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. In addition, it manufactures and sells animal nutrition and health products. It also exports its products. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.
Farmaceutica REMEDIA S.A. (BVB:RMAH)
GlaxoSmithKline Consumer Healthcare, Inc.
Drug Retail
Farmaceutica REMEDIA S.A. (BVB:RMAH) 2020 Form 
Business Description: Farmaceutica REMEDIA S.A. operates a chain of pharmacies in Romania. The company is also involved in the wholesale distribution of drugs to pharmacies, and public and private hospitals and clinics. In addition, it provides logistics, recordings, promotion and marketing of drugs, etc., as well as pharmaceutical products registration services. The company was incorporated in 1991 and is headquartered in Deva, Romania.
Farmaceutica REMEDIA S.A. (BVB:RMAH)
GSK plc (LSE:GSK)
Drug Retail
Farmaceutica REMEDIA S.A. (BVB:RMAH) 2019 Form Doc
Business Description: Farmaceutica REMEDIA S.A. operates a chain of pharmacies in Romania. The company is also involved in the wholesale distribution of drugs to pharmacies, and public and private hospitals and clinics. In addition, it provides logistics, recordings, promotion and marketing of drugs, etc., as well as pharmaceutical products registration services. The company was incorporated in 1991 and is headquartered in Deva, Romania.
Five Prime Therapeutics, Inc.
Glaxo Group Limited
Biotechnology
Five Prime Therapeutics, Inc. 2020 Form 10-K
Business Description: Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company’s product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors. Its preclinical programs include FPA157, an anti-CCR8 antibody that is engineered to eliminate CCR8-expressing CD4+ regulatory T cells within solid tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, and BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California. As of April 16, 2021, Five Prime Therapeutics, Inc. operates as a subsidiary of Amgen Inc.
GSK plc (LSE:GSK)
Qura Therapeutics, LLC
Pharmaceuticals
GSK plc (LSE:GSK) 2021 Form 20-F
Business Description: GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
HCR Co., Ltd (SHSE:688500)
GSK plc (LSE:GSK)
Research and Consulting Services
HCR Co., Ltd (SHSE:688500) - Form 
Business Description: HCR Co., Ltd. provides various data intelligence solutions in China. It offers solutions in field of data insight and focusing on the essence of business. The company assists the government to enhance the efficiency of management; and help enterprises to enhance efficiency and revenue, make accurate decision, and reshape their business with the whole data driven and the artificial intelligence. It serves automobile, internet technology, consumer durable, healthcare, industrial sector, tourism, public affairs, telecom, retail, FMCG, finance, tobacco, environmental protection, and education industries. The company was founded in 2008 and is headquartered in Beijing, China.
IDEAYA Biosciences, Inc. (NasdaqGS:IDYA)
Glaxosmithkline Intellectual Property (No.4) Limited
Biotechnology
IDEAYA Biosciences, Inc. (NasdaqGS:IDYA) 2021 Form 10-K
Business Description: IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company’s lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences, Inc. (NasdaqGS:IDYA)
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company’s lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Ildong Pharmaceutical Co., Ltd. (KOSE:A249420)
GSK plc (LSE:GSK)
Pharmaceuticals
Ildong Pharmaceutical Co., Ltd. (KOSE:A249420) - Form 
Business Description: Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong’s proprietary projects through access to Evotec’s INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Ildong Pharmaceutical Co., Ltd. (KOSE:A249420)
N.V. Novartis Consumer Health S.A.
Pharmaceuticals
Key DevelopmentClient Announcements Dec-05-2019
Business Description: Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong’s proprietary projects through access to Evotec’s INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Immunocore Holdings plc (NasdaqGS:IMCR)
GlaxoSmithKline Intellectual Property Development Limited
Biotechnology
Immunocore Holdings plc (NasdaqGS:IMCR) 2021 Form 424B4
Business Description: Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Innoviva, Inc. (NasdaqGS:INVA)
Glaxo Group Limited
Pharmaceuticals
Innoviva, Inc. (NasdaqGS:INVA) 2020 Form 10-K
Business Description: Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Insmed Innovation UK Limited (Acquired)
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: As of June 30, 2023, Adrestia Therapeutics Ltd was acquired by Insmed Incorporated. Adrestia Therapeutics Ltd engages in developing therapeutics that work in restoring the biological balance in damaged, diseased, and dying cells. It offers basic research, applied research, and experimental development services for biotechnology industry. The company was incorporated in 2017 and is based in Cambridge, United Kingdom.
Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS)
Glaxo Group Limited
Biotechnology
Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS) 2019 Form 10-Q
Business Description: Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS)
GlaxoSmithKline Intellectual Property Development Limited
Biotechnology
Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS) 2019 Form 10-Q
Business Description: Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
JCR Pharmaceuticals Co., Ltd. (TSE:4552)
GSK plc (LSE:GSK)
Pharmaceuticals
JCR Pharmaceuticals Co., Ltd. (TSE:4552) - Form 
Business Description: JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
KineMed, Inc.
Glaxo Group Limited
Life Sciences Tools and Services
KineMed, Inc. 2014 Form S-1
Business Description: KineMed, Inc. develops and commercializes proprietary biomarker platform technology. The company focuses on applying its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests. It plans to commercialize biomarkers in the areas of muscle biology, fibrotic diseases, neurodegenerative diseases, cardiometabolic diseases, skin care, and cancer. The company has a strategic collaboration with Pfizer Inc. to discover and develop novel proprietary biomarkers in various fields of unmet medical need; and an agreement with BioPharma Forest, Inc. to develop and commercialize synthetic Ghrelin. KineMed, Inc. was founded in 2001 and is based in Emeryville, California.
King's College London
GSK plc (LSE:GSK)
Education Services
GSK plc (LSE:GSK) - Form Doc
Business Description: King's College London is a university college in the tradition of the Church of England. King's College London was founded in 1829 and is based in London, United Kingdom.
Koninklijke Philips N.V. (ENXTAM:PHIA)
GSK plc (LSE:GSK)
Health Care Equipment
GSK plc (LSE:GSK) - Form Doc
Business Description: Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental solutions; and grooming and beauty products and solutions. It has strategic partnership agreements with TriHealth, Prisma Health, and the University Health System of San Antonio to help the health system standardize patient monitoring, drive interoperability, and lay the foundation for enterprise-wide platform; and Oulu University Hospital to deliver advanced image-guided therapy solutions. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Kymera Therapeutics, Inc. (NasdaqGM:KYMR)
GlaxoSmithKline Intellectual Property Development Limited
Biotechnology
Kymera Therapeutics, Inc. (NasdaqGM:KYMR) 2021 Form 10-K
Business Description: Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
LifeMine Therapeutics, Inc.
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company has a strategic collaboration with GlaxoSmithKline. LifeMine Therapeutics, Inc. was formerly known as LifeMine Biotherapeutics, Inc. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional location in Gloucester, Massachusetts.
Liquidia Corporation (NasdaqCM:LQDA)
Glaxo Group Limited
Pharmaceuticals
Liquidia Corporation (NasdaqCM:LQDA) 2019 Form 8-K
Business Description: Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Liquidia Corporation (NasdaqCM:LQDA)
Glaxosmithkline Biologicals S.A.
Pharmaceuticals
Liquidia Corporation (NasdaqCM:LQDA) 2018 Form DRS/A
Business Description: Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Liquidia Corporation (NasdaqCM:LQDA)
GSK plc (LSE:GSK)
Pharmaceuticals
Liquidia Corporation (NasdaqCM:LQDA) 2019 Form 424B4
Business Description: Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Lyell Immunopharma, Inc. (NasdaqGS:LYEL)
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T‑cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c‑Jun overexpression and NR4A3 gene knockout, to endow resistance to T‑cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi‑R to generate population of T cells with durable stemness, and Stim‑R, a proprietary synthetic cell mimetic. The company’s pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T‑cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Malin Corporation plc (ISE:MLC)
GSK plc (LSE:GSK)
Life Sciences Tools and Services
Malin Corporation plc (ISE:MLC) - Form Doc
Business Description: Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It also provides company secretarial services and engages in investment activities. The company was incorporated in 2014 and is headquartered in Dublin, Ireland.
Medicago Inc.
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: Medicago Inc., a clinical-stage biotechnology company, develops novel vaccines and therapeutic proteins to treat various infectious diseases worldwide. The company develops its vaccines based on its proprietary technologies comprising the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidates include H5N1 pandemic influenza VLP vaccine, which has completed a Phase II human clinical trial; and seasonal influenza and H1N1 vaccines. The company’s products under development also comprise non-influenza VLP and rabies vaccine candidates. It has a strategic alliance with Mitsubishi Tanabe Pharma Corporation to develop a Rotavirus vaccine candidate; research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases for the development of a plant-based VLP vaccine candidate for the prevention of Ebola; and collaboration with GSK to develop and evaluate a COVID-19 candidate vaccine combining Medicago's recombinant Coronavirus Virus-Like Particles with GSK's pandemic adjuvant system. Medicago Inc. was incorporated in 1997 and is headquartered in Quebec, Canada. As of September 18, 2013, Medicago Inc. operates as a subsidiary of Mitsubishi Tanabe Pharma Corporation.
Medical Union Pharmaceuticals Company
GSK plc (LSE:GSK)
Pharmaceuticals
Medical Union Pharmaceuticals Company - Form 
Business Description: Medical Union Pharmaceuticals Company develops, manufactures, and distributes generic and pharmaceutical products in Egypt. The company offers products that cover various therapeutic areas, including gastroenterology, dermatology, gynecology, andrology, cardiovascular, dentistry, anti-infectives, anti-histaminics, analgesics and anti-rheumatics, endocrinology, hepatology, respiratory, and neurology, as well as vitamins and tonic products. It also exports its products to approximately 30 countries. Medical Union Pharmaceuticals Company is headquartered in Cairo, Egypt.
Merck KGaA (XTRA:MRK)
GSK plc (LSE:GSK)
Pharmaceuticals
Merck KGaA (XTRA:MRK) 2021 Form 
Business Description: Merck KGaA operates as a science and technology company in Germany. The company’s Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company’s Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
MINAPHARM Pharmaceuticals (CASE:MIPH)
GSK plc (LSE:GSK)
Pharmaceuticals
MINAPHARM Pharmaceuticals (CASE:MIPH) - Form 
Business Description: MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East. The company’s products include Angiofox capsules, Artelac and Berberil eye drops; Bon-one, Ciprodiazole, Dumozol, Hydroquine, and Burinex tablets; Chlorhexidine; DICYNONE; Corneregel fluid and ophthalmic gel; Betolvex and Fleboton ampoules; Deponit patches; Dexagel viscous eye drops; Doxiproct plus and Doxiproct ointment; Doxium capules; Broncho-Vaxom capsules for adults and infants; Broncho-Vaxom infant sachets; Netophtiole plus eye drops; Extrauma cream; and Ophtatrov and Optatrov plus. It also provides Ferroduonal, Lipanthyl, Parafon, Ribavirin, Uro-Vaxom, Ursofalk, Ursoplus, Ursotwin, and Ferro Sanol Gyn capsules; Gyno-Pevaryl, Pevisone, Srilane, and Pevaryl cream; Gonapure; Hair Plus Back 2% and 5%; Hair Plus Back Topical FOAM; Lucidril 500; Lucidril, Salofalk, Trimed flu, XerovirinC, Pixcolt, and Ossopan tablets; Thrombexx ampoules, cream, and gel; Vidisept N drops; and Luciforte, Oxytocin, Reiferon Retard, and Nausilex ampoules. The company offers its products for the treatment of hematoma and thrombosis, iron deficiency anemia, recurrent urinarytract infections, immunostimulants, osteoporosis, renal osteodystrophy, loop diuretics, prophylaxis, hemorrhoids, rheumatoid arthritis, hyperlipidemia, alopecia, skin infections, topical corticosteroids, gynecological antifungals, vaginal infections, anti-infective, dyslipidemia, muscle spasm, dry eye, eye inflammation and allergy, corneal, nausea and vomiting, hepatology and gastroenterology, coronary heart, respiratory tract infections, occular irritation, labour induction, cerebral insufficiency, surgical dressing, prophylaxis, pregnancy and lactation, hemostasis, hemorrhage, infertility, and microvascular diseases, as well as vitamin B12 deficiency, anemia, and diabetic neuropathy. The company was founded in 1958 and is headquartered in Cairo, Egypt.
Myriad Genetics, Inc. (NasdaqGS:MYGN)
GSK plc (LSE:GSK)
Biotechnology
Myriad Genetics, Inc. (NasdaqGS:MYGN) 2021 Form 10-KT
Business Description: Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Novartis AG (SWX:NOVN)
GSK plc (LSE:GSK)
Pharmaceuticals
GSK plc (LSE:GSK) - Form Doc
Business Description: Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Nuevolution AB (publ)
GSK plc (LSE:GSK)
Biotechnology
Nuevolution AB (publ) - Form Doc
Business Description: Nuevolution AB (publ), a biopharmaceutical company, focuses on developing drug treatments for oncology and chronic inflammatory diseases. The company offers Chemetics, a drug discovery platform, which enables the discovery of small molecule drug candidates. It develops ROR?t Inhibitor for the treatment of chronic inflammatory diseases; Bromodomain BET BD1 selective inhibitor to treat chronic inflammatory diseases and cancer; and IL-17A inhibitor program for chronic inflammatory diseases. The company also develops ROR?t Agonist to treat immuno-oncology; and GRP78 for the treatment of oncology. It has license and collaboration agreements with Amgen; Almirall; and Janssen Biotech, Inc. Nuevolution AB (publ) was founded in 2001 and is headquartered in Copenhagen, Denmark. Nuevolution AB (publ) operates as a subsidiary of Amgen Inc.
Paraytec Limited
GSK plc (LSE:GSK)
Health Care Equipment
Braveheart Investment Group plc (AIM:BRH) 2019 Form Doc
Business Description: Paraytec Limited designs, develops, manufactures, and distributes solutions for pharmaceutical and biopharmaceutical applications. It offers ActiPix ultraviolet (UV) imaging system; Viscosizer TD, an automated biophysical characterization tool that offers biopharmaceutical researchers with an orthogonal technique for conformational stability analysis; and ActiPix D100 UV area imaging system for UV-Vis absorbance detection, and enables multiplex detection for the research and OEM communities. It provides applications for ActiPix™ detectors, which include lab on capillary, biocatalysis, protein digests, bioprocessing, indirect detection, and lab on a chip. The company also offers contract research services. The company was incorporated in 2005 and is based in York, United Kingdom.
PathAI, Inc.
GSK plc (LSE:GSK)
Life Sciences Tools and Services
Key DevelopmentClient Announcements Apr-05-2022
Business Description: PathAI, Inc. operates a life sciences tools and service company that develops artificial intelligence-based technology solutions and research tools for pathology laboratories. The company's Biopharma services include discovery and translational research, clinical development, diagnostic development, and commercialization, Biopharma lab services include full anatomic and digital pathology lab services sample receipt, grossing, processing, sectioning, staining, and scanning with turnaround. The company’s platform identifies biomarkers and analyzes new associations to create important insights about mechanism of action, pharmacodynamics, patient selection, and stratification. The company‘s AI technology to improve patient outcomes through accurate diagnosis, more lifesaving drug approvals, and matching with effective treatments. It develops precision AI technology to assists pathologists in making rapid and accurate diagnosis for patients. The company also builds solutions to help identify patients that benefit from novel therapies to make scalable personalized medicine a reality. Additionally, it also provides clinical trial services. PathAI, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts with an additional office in Austin, Texas.
PeptiDream Inc. (TSE:4587)
GSK plc (LSE:GSK)
Biotechnology
PeptiDream Inc. (TSE:4587) - Form 
Business Description: PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. The company, through its subsidiary PDRadiopharma Inc., is involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.
Pfizer Inc. (NYSE:PFE)
GSK plc (LSE:GSK)
Pharmaceuticals
GSK plc (LSE:GSK) - Form Doc
Business Description: Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Qura Therapeutics, LLC
GSK plc (LSE:GSK)

GSK plc (LSE:GSK) - Form Doc
Business Description: Qura Therapeutics, LLC operates as a subsidiary of Glaxosmithkline Plc.
Samil Pharmaceutical Co.,Ltd (KOSE:A000520)
GSK plc (LSE:GSK)
Pharmaceuticals
Samil Pharmaceutical Co.,Ltd (KOSE:A000520) - Form 
Business Description: Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
Sanofi (ENXTPA:SAN)
GSK plc (LSE:GSK)
Pharmaceuticals
GSK plc (LSE:GSK) 2023 Form 20-F
Business Description: Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Santarus, Inc.
Glaxo Group Limited
Pharmaceuticals
Santarus, Inc. 2013 Form 10-K
Business Description: Santarus, Inc., a specialty biopharmaceutical company, focuses on acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company offers UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis; and ZEGERID (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders. It also provides GLUMETZA (metformin hydrochloride extended release tablets) and CYCLOSET (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE (fenofibrate) tablets, which are indicated as an adjunct to diet to reduce high cholesterol. Santarus' product development pipeline includes the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema. It is also developing Rifamycin SV MMX, which is in Phase III clinical testing for the treatment of travelers' diarrhea. In addition, the company has completed a Phase I clinical program with SAN-300, an investigational monoclonal antibody. Santarus, Inc. was founded in 1996 and is headquartered in San Diego, California. As of December 31, 2013, Santarus, Inc. operates as a subsidiary of Salix Pharmaceuticals, Inc.
Saudi Pharmaceutical Industries and Medical Appliances Corporation (SASE:2070)
GSK plc (LSE:GSK)
Pharmaceuticals
Saudi Pharmaceutical Industries and Medical Appliances Corporation (SASE:2070) - Form 
Business Description: Saudi Pharmaceutical Industries and Medical Appliances Corporation develops, manufactures, and markets medicinal and pharmaceutical products in the Kingdom of Saudi Arabia. The company is also involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics, as well as engages in wholesale and retail of medicines and related products. It operates and maintains healthcare facilities. In addition, the company engages in the research and development of medical science activities. The company was founded in 1986 and is based in Buraydah, the Kingdom of Saudi Arabia.
Shenzhen Neptunus Interlong Bio-technique Company Limited (SEHK:8329)
GlaxoSmithKline Pte Ltd
Pharmaceuticals
Shenzhen Neptunus Interlong Bio-technique Company Limited (SEHK:8329) 2013 Form Doc
Business Description: Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines and medical devices in the People’s Republic of China. The company offers medicines for various therapeutic areas, including oncology, cardiovascular system, respiratory system, digestive system, and mental disorders. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology business. The company is based in Shenzhen, the People’s Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
Shionogi & Co., Ltd. (TSE:4507)
GSK plc (LSE:GSK)
Pharmaceuticals
GSK plc (LSE:GSK) - Form Doc
Business Description: Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay, an anti-HIV drug. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, and Refractory/unexplained chronic cough; Zuranolone for Depression; SDT-001, Inattentive ADHD pediatric; BPN14770 for Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamous cell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Shionogi & Co., Ltd. (TSE:4507)
ViiV Healthcare UK Limited
Pharmaceuticals
Shionogi & Co., Ltd. (TSE:4507) - Form Doc
Business Description: Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay, an anti-HIV drug. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, and Refractory/unexplained chronic cough; Zuranolone for Depression; SDT-001, Inattentive ADHD pediatric; BPN14770 for Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamous cell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Shutterstock, Inc. (NYSE:SSTK)
ViiV Healthcare Limited
Interactive Media and Services
Key DevelopmentClient Announcements Dec-01-2020
Business Description: Shutterstock, Inc., a technology company, provides quality content, and creative workflow solutions in North America, Europe, and internationally. It offers image services consisting of photographs, vectors, and illustrations, which is used in visual communications, such as websites, digital and print marketing materials, corporate communications, books, publications, and others; footage services, including video clips, filmed by industry experts and cinema grade video effects, and HD and 4K formats that are integrated into Websites, social media, marketing campaigns, and cinematic productions; and music services comprising music tracks and sound effects, which are used to complement images and footage. The company provides its services under the Shutterstock, Bigstock, Offset, TurboSquid,PremiumBeat brand names, as well as Application programming interface to enhance workflow and project management needs, and search capabilities. It serves corporate professionals and organizations, media and broadcast companies, and small and medium-sized businesses, and individual creators. The company was founded in 2003 and is headquartered in New York, New York.
SK bioscience Co.,Ltd. (KOSE:A302440)
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
SpeeDx Pty Ltd
GSK plc (LSE:GSK)
Biotechnology
Key DevelopmentClient Announcements Jun-24-2019
Business Description: SpeeDx Pty Ltd., a medical diagnostic company, is focused on the research, development, and commercialization of molecular diagnostic detection technologies and in vitro diagnostic tests. The company offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for the sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of targets; and MNAzyme quantitative PCR, a method that combines target specific interrogation and signal generation using universal reporter probes. It also offers DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health, and diagnostic and therapeutic applications; PASS, a design feature for primers and/or MNAzyme components that is used for highly sensitive multiplexed detection of gene mutations, allelic variations, and viral and bacterial strains; EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes; and DNA-only-cascade, an isothermal signal amplification cascade that utilizes catalytic nucleic acid enzymes. SpeeDx Pty Ltd. has a strategic partnership with Thermo Fisher Scientific Inc. The company was founded in 2009 and is based in Eveleigh, Australia.
SpringWorks Therapeutics, Inc. (NasdaqGS:SWTX)
GSK plc (LSE:GSK)
Biotechnology
Key DevelopmentClient Announcements Sep-07-2022
Business Description: SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.
Syngene International Limited (NSEI:SYNGENE)
GSK plc (LSE:GSK)
Life Sciences Tools and Services
Biocon Limited (NSEI:BIOCON) - Form Doc
Business Description: Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, Japan, Europe, the United States, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, clinical data management, regulatory, biostatistics, and medical writing services. Further, it offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Takeda Pharmaceutical Company Limited (TSE:4502)
GSK plc (LSE:GSK)
Pharmaceuticals
Takeda Pharmaceutical Company Limited (TSE:4502) 2020 Form 20-F
Business Description: Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, JCR Pharmaceuticals, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Tempus Labs, Inc.
GSK plc (LSE:GSK)
Health Care Technology
Key DevelopmentStrategic Alliances Oct-18-2022
Business Description: Tempus Labs, Inc. develops a library of molecular and clinical data and an operating system to make that information accessible and useful for patients, physicians, and researchers across the United States. The company develops tools to collect, cleanse, and analyze molecular and clinical data, enabling physicians to make real-time data-driven decisions to deliver personalized patient care, as well as facilitate the discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. It offers genomic sequencing, clinical data restructuring, image recognition, and biological modeling services, as well as analyzes molecular and therapeutic data for making real-time decisions. Its tools have applications in oncology, neurology, psychiatry, research, life sciences, and infectious diseases. Tempus Labs, Inc. was formerly known as Bioin, Inc. The company was incorporated in 2015 and is based in Chicago, Illinois with additional locations in New York, New York; Redwood Shores, California; Durham, North Carolina; Peachtree Corners, Georgia; Washington, District of Columbia; and Barcelona, Espana.
Theravance Respiratory Company, LLC
Glaxo Group Limited

Innoviva, Inc. (NasdaqGS:INVA) 2020 Form 10-K
Business Description: Theravance Respiratory Company, LLC was incorporated in 2013 and is based in Delaware. As of July 20, 2022, Theravance Respiratory Company, LLC operates as a subsidiary of Royalty Pharma plc.
University Of Greenwich
GSK plc (LSE:GSK)
Education Services
University Of Greenwich - Form Doc
Business Description: University Of Greenwich is based in London, United Kingdom.
University of Oxford
GSK plc (LSE:GSK)
Education Services
GSK plc (LSE:GSK) - Form Doc
Business Description: University of Oxford is an educational institution that provides undergraduate, graduate, postgraduate, research, continuing education, and distance learning programs. The university primarily offers courses in the areas of medical sciences, mathematical, physical, life sciences, humanities, and social science academic departments. It also provides student services, including careers and counselling, as well as resources, such as libraries, laboratories, and museums; and engages in teaching, research, and publishing and related activities. University of Oxford was founded in 1096 and is based in Oxford, United Kingdom.
VBI Vaccines Inc. (NasdaqCM:VBIV)
Glaxosmithkline Biologicals S.A.
Biotechnology
VBI Vaccines Inc. (NasdaqCM:VBIV) 2021 Form 10-K
Business Description: VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Vectura Group plc
GSK plc (LSE:GSK)
Pharmaceuticals
Vectura Group plc 2020 Form Doc
Business Description: Vectura Group plc engages in the development of pharmaceutical therapies for the treatment of airways-related diseases. Vectura Group plc was formerly known as Vectura Limited and changed its name to Vectura Group plc in June 2004. The company was incorporated in 1997 and is based in Wiltshire, United Kingdom. As of September 16, 2021, Vectura Group plc operates as a subsidiary of PMI Global Services, Inc.
Viome Life Sciences, Inc.
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: Viome Life Sciences, Inc. is an AI-driven, personalized therapeutics platform that digitize, decode, and decipher human biology for the prevention and early detection of chronic diseases, and application that empowers people with data and technology based on the functional analysis of microbial, mitochondrial, and human gene expression. The company’s services include access to the Viome public website, mobile application, Viome Precision Supplements, and Viome Precision Probiotics +Prebiotics tests, subscription services, and personal omics testing services which includes microbiome, genetic, and transcriptome, and Viome Discovery tests that includes collection and analysis of stool, blood, saliva, and other biological samples. It sells its products through distributors, as well as online. The company was formerly known as Bluespin, Inc. Viome Life Sciences, Inc. was incorporated in 2016 and is based in Bellevue, Washington. Life Sciences, Inc. operates as a subsidiary of BlueDot LLC.
Vir Biotechnology, Inc. (NasdaqGS:VIR)
Beecham S.A.
Biotechnology
Vir Biotechnology, Inc. (NasdaqGS:VIR) 2020 Form 424B4
Business Description: Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc. (NasdaqGS:VIR)
Glaxo Wellcome UK Ltd.
Biotechnology
Vir Biotechnology, Inc. (NasdaqGS:VIR) 2020 Form 424B4
Business Description: Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc. (NasdaqGS:VIR)
Glaxosmithkline Biologicals S.A.
Biotechnology
Key DevelopmentStrategic Alliances Apr-06-2020
Business Description: Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc. (NasdaqGS:VIR)
GlaxoSmithKline Intellectual Property Development Limited
Biotechnology
Key DevelopmentStrategic Alliances Apr-06-2020
Business Description: Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc. (NasdaqGS:VIR)
GlaxoSmithKline Trading Services Limited
Biotechnology
Vir Biotechnology, Inc. (NasdaqGS:VIR) 2020 Form 8-K
Business Description: Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc. (NasdaqGS:VIR)
GSK plc (LSE:GSK)
Biotechnology
GSK plc (LSE:GSK) - Form Doc
Business Description: Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Xinhuanet Co., Ltd. (SHSE:603888)
GSK plc (LSE:GSK)
Publishing
Xinhuanet Co., Ltd. (SHSE:603888) - Form 
Business Description: Xinhuanet Co., Ltd. operates a news information service portal in China. The company publishes news from 31 local channels; and from English, French, Spanish, Russian, Arabic, Japanese, Korean, German, Portuguese, Cyrillic, Mongolian and other foreign language websites and clients. It also provides online advertising and information services; multimedia information services, big data intelligent analysis services, and large-scale forums and conferences; network technology services, such as website construction, content management, operation and maintenance, and technical services; digital content; and mobile internet services. The company was founded in 2000 and is headquartered in Beijing, China. Xinhuanet Co., Ltd. is a subsidiary of Xinhua News Agency.
Zhejiang Juhua Co., Ltd. (SHSE:600160)
GSK plc (LSE:GSK)
Commodity Chemicals
Zhejiang Juhua Co., Ltd. (SHSE:600160) - Form 
Business Description: Zhejiang Juhua Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells chemical raw materials, chemical products, and food additives in China. It offers refrigerant, petrochemical materials, fluorine chemical raw materials, fluorine-containing polymer materials, food packaging materials, fluorine-containing fine chemicals, basic chemical products, and other products under the JH Juhua brand. The company also engages in gas cylinder inspection, and consultation and technology transfer business, as well as offers relevant technical services. Its products are used in daily life and national defense, aerospace, electronic information, environmental protection, new energy, electrical, electrical appliances, chemical industry, machinery, instrumentation, construction, textile, metal surface treatment, pharmaceutical, medical, textile, food, metallurgical smelting, and other industrial sectors. The company also exports its products. Zhejiang Juhua Co., Ltd. was incorporated in 1998 and is headquartered in Quzhou, China.
Zymeworks Inc. (NasdaqGS:ZYME)
GlaxoSmithKline Intellectual Property Development Limited
Biotechnology
Zymeworks Inc. (NasdaqGS:ZYME) 2021 Form 10-K
Business Description: Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
*denotes proprietary relationship